Capital World Investors Makes New Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Capital World Investors purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 748,230 shares of the biopharmaceutical company's stock, valued at approximately $35,773,000. Capital World Investors owned approximately 0.59% of Halozyme Therapeutics at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Heck Capital Advisors LLC bought a new position in shares of Halozyme Therapeutics in the fourth quarter valued at about $29,000. CBIZ Investment Advisory Services LLC bought a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at $29,000. Smartleaf Asset Management LLC raised its position in shares of Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 197 shares during the period. Venturi Wealth Management LLC bought a new position in Halozyme Therapeutics in the fourth quarter valued at approximately $69,000. Finally, Parkside Financial Bank & Trust lifted its position in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after acquiring an additional 322 shares in the last quarter. Institutional investors own 97.79% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on HALO shares. JPMorgan Chase & Co. upped their price objective on Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Wells Fargo & Company decreased their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. HC Wainwright reaffirmed a "buy" rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research report on Friday. Piper Sandler increased their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Finally, Benchmark restated a "buy" rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $62.89.

Halozyme Therapeutics Stock Performance

Shares of HALO stock traded up $1.24 during midday trading on Friday, hitting $60.49. 992,970 shares of the company were exchanged, compared to its average volume of 1,435,271. The firm has a market capitalization of $7.47 billion, a P/E ratio of 17.64, a PEG ratio of 0.42 and a beta of 1.32. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. Halozyme Therapeutics, Inc. has a 52 week low of $37.97 and a 52 week high of $66.00. The firm's 50 day moving average price is $60.50 and its two-hundred day moving average price is $55.09.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. As a group, equities research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 503 shares of the firm's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total value of $32,217.15. Following the sale, the director now owns 33,108 shares of the company's stock, valued at approximately $2,120,567.40. This trade represents a 1.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the sale, the senior vice president now directly owns 185,453 shares in the company, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,200 shares of company stock valued at $1,286,568 in the last quarter. Company insiders own 2.90% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.